GENE LOGIC ENTERS AGREEMENT WITH PFIZER TO REPOSITION SIGNIFICANT NUMBER OF DRUG CANDIDATES
Gene Logic Inc. (NASDAQ: GLGC) announced today that it has entered into an agreement with Pfizer Inc. to seek new therapeutic indications for a significant number of unapproved drug candidates that are not currently in active development. The drug candidates originated from across Pfizer's portfolio of therapeutic areas. Similar to development stage in-licensing deals, the terms of the agreement provide for success-based milestones per compound and royalties on the commercialization of drugs repositioned through Gene Logic's Drug Repositioning Program. Full terms of the agreement were not disclosed.
Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20050927005410&newsLang=en)
Upcoming Events
-
21Oct